Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Thailand OEM insole and pillow supplier

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Graphene insole OEM factory China

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.ODM pillow for sleep brands Vietnam

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Vietnam ODM expert for comfort products

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Taiwan insole ODM full-service provider factory

Scientists have discovered that orb weaver spiders’ web glue properties evolve based on the species’ living environment. By studying Argiope argentata and Argiope trifasciata species that inhabit dry and humid environments respectively, researchers found that although the web glue consists of similar proteins, the proportions differ, affecting the glue’s properties. The glue’s ability to absorb water from the atmosphere and its stickiness are crucial for the spiders’ survival, and understanding these adaptations could have potential applications in industry, medicine, and beyond. The genes of orb weaver spiders from different environments are very similar, but their glue proteins and glue properties differ greatly due to differential gene expression. Orb weaver spiders make the capture threads of their webs sticky with an aqueous glue made in special aggregate glands. Scientists studied different species living in different environments to see how the glue changed and found that although the glue was mostly made of the same components, the proportions of the proteins involved were different, changing the glue’s properties. Spiders that don’t weave good silk don’t get to eat. The silk spiders produce which creates their webs is key to their survival – but spiders live in many different places which require webs fine-tuned for local success. Scientists studied the glue that makes orb weaver spiders’ webs sticky to understand how its material properties vary in different conditions. “Discovering the sticky protein components of biological glues opens the doors to determining how material properties evolve,” said Dr Nadia Ayoub of Washington and Lee University, co-corresponding author of the study published in Frontiers in Ecology and Evolution. “Spider silk fibers and glues represent a fantastic model for answering such questions since they are primarily made of proteins and proteins are encoded by genes.” “Spider silks and glues have huge biomimetic potential,” added Dr Brent Opell of Virginia Tech, co-corresponding author. “Spiders make glues with impressive properties that would have applications in industry, medicine, and beyond.” Tangled Up in Spider Webs Each strand of an orb weaver spider’s web contributes to the capture of food. The web has a stiff frame which absorbs the impact of prey, which are then trapped by sticky lines until the spider can tackle them. These lines are made sticky by an aqueous glue synthesized in aggregate glands. The glue absorbs water from the atmosphere and needs to be optimized to achieve the best stickiness results for the local humidity. But there are many species of orb weaver spider living in different environments, which means their glue must adapt to different levels of humidity. To understand how spider glue stickiness adapts, Ayoub and her colleagues focused on two species, Argiope argentata — which lives in dry environments — and Argiope trifasciata, which lives in humid environments. The team collected webs from A. trifasciata in the wild and had A. argentata spiders build webs in the lab. To ensure that these webs were equivalent to webs in the wild, the scientists fed the spiders a diet comparable to their usual prey and compared glue droplet volume to wild controls to make sure that the humidity in the lab wasn’t affecting the droplets’ properties. They then analyzed the proteins in the glue and the droplets’ material properties. A Sticky Situation The team found that droplets from A. argentata spiders are smaller than those from A. trifasciata and absorb less water as local humidity increases. They also had smaller protein cores, occupying a smaller proportion of the droplet’s volume, and absorbed less water from the atmosphere. The toughness of glue droplets for both species of spider is based on the stiffness of the protein core of the droplets, and A. argentata protein core toughness decreased as the humidity went up. A. argentata thread glue droplets were generally more closely spaced and stickier. The scientists also analyzed the proteins found in the glue droplets to understand how these differences in material properties arise from the proteins. Although the proteins they found were similar, they appeared in different proportions, and A. argentata glue contained the protein products of four genes that didn’t appear in A. trifasciata glue. These extra proteins and a more balanced ratio of AgSp1 and AgSp2 proteins may explain both the greater toughness of this glue and its lower capacity for water absorption. “Despite the dramatic differences in material properties, the two species share most of their protein components,” said Opell. “The sequences of these proteins are also similar between species, but the relative abundance of individual proteins differs. Modifying the ratios of proteins is likely a rapid mechanism to adjust material properties of biological glues.” “This study only examined two species, so our proposed relationships between proteins and material properties are limited,” cautioned Ayoub. “However, we are in the process of documenting protein components and material properties of a diverse set of species, which will allow more power to detect the mechanisms of how proteins give rise to material properties.” Reference: “Orb weaver aggregate glue protein composition as a mechanism for rapid evolution of material properties” by Nadia A. Ayoub, Lucas DuMez, Cooper Lazo, Maria Luzaran, Jamal Magoti, Sarah A. Morris, Richard H. Baker, Thomas Clarke, Sandra M. Correa-Garhwal, Cheryl Y. Hayashi, Kyle Friend and Brent D. Opell, 18 April 2023, Frontiers in Ecology and Evolution. DOI: 10.3389/fevo.2023.1099481 Funding: National Science Foundation, National Science Foundation, National Science Foundation, Washington and Lee University

In the pursuit of new antibiotics, researchers surveyed thousands of gut microbiomes, discovering potential antibiotics using AI to mine genetic data. Over half of the identified peptides showed antimicrobial effectiveness, including a promising candidate comparable to the FDA-approved polymyxin B. Researchers have discovered several new antibiotic candidates by mining gut microbiome data, with one matching the effectiveness of established antibiotics. There are approximately 100 trillion microbes in the average human gut, many of which are constantly competing for limited resources. “It’s such a harsh environment,” says César de la Fuente, Presidential Assistant Professor in Bioengineering and in Chemical and Biomolecular Engineering within the School of Engineering and Applied Science, in Psychiatry and Microbiology within the Perelman School of Medicine, and in Chemistry within the School of Arts & Sciences. “You have all these bacteria coexisting, but also fighting each other. Such an environment may foster innovation.” In this hostile environment, where bacteria are forced to develop tools to fight against one another, de la Fuente’s lab sees potential for new antibiotics to fight drug-resistant infections. Prevotellin-2, an antibiotic discovered in the human gut microbiome, demonstrated anti-infective capabilities on par with polymyxin B, an FDA-approved antibiotic used today to treat multidrug-resistant infections, suggesting that the human gut microbiome may contain antibiotics that will someday find clinical application. Credit: Cesar de la Fuente and Ami S. Bhatt Advancements in Antibiotic Discovery In a new paper in Cell, the labs of de la Fuente and Ami S. Bhatt, Professor in Medicine (Hematology) and Genetics at Stanford, surveyed the gut microbiomes of nearly 2,000 people, discovering dozens of potential new antibiotics. “We think of biology as an information source,” says de la Fuente. “Everything is just code. And if we can come up with algorithms that can sort through that code, we can dramatically accelerate antibiotic discovery.” Recently, de la Fuente’s lab has made headlines for finding antibiotic candidates everywhere from the genetic information of extinct creatures like Neanderthals and wooly mammoths to masses of bacteria whose genetic material the lab analyzed using artificial intelligence. “One of our primary goals is to mine the world’s biological information as a source of antibiotics and other useful molecules,” says de la Fuente. “Rather than relying on traditional, painstaking methods that involve collecting soil or water samples and purifying active compounds, we harness the vast array of biological data found in genomes, metagenomes, and proteomes. This allows us to uncover new antibiotics at digital speed.” Penn Engineering and Stanford researchers used AI to help identify dozens of potential antibiotic candidates, by analyzing the genetic sequences in nearly 2,000 different human gut microbiomes. Credit: Cesar de la Fuente and Ami S. Bhatt Innovative Research Methods Given that bacteria evolve quickly, de la Fuente and his coauthors hypothesized that an environment that encourages competition — like the human gut — might be home to numerous undiscovered antimicrobial compounds. “When there is a lack of resources,” de la Fuente points out, “that’s when biology really comes up with innovative solutions.” The group focused on peptides, short chains of amino acids, which have previously shown promise as novel antibiotics. “We computationally mined over 400,000 proteins,” de la Fuente says, referring to the process whereby AI reads the letters of genetic code and, having been trained on a set of known antibiotics, predicts which genetic sequences might have antimicrobial properties. Promising Results and Future Prospects “Interestingly, these molecules have a different composition from what has traditionally been considered antimicrobial,” says Marcelo D.T. Torres, a research associate in the de la Fuente lab, and the paper’s first author. “The compounds we have discovered constitute a new class, and their unique properties will help us understand and expand the sequence space of antimicrobials.” Of course, those predictions must then be experimentally validated; after finding a few hundred antibiotic candidates, the researchers selected 78 to test against actual bacteria. After synthesizing these peptides, the researchers exposed bacterial cultures to each peptide and waited 20 hours to see which peptides successfully inhibited bacterial growth. In addition, the team later tested the antibiotic candidates in animal models. Over half of the peptides tested worked — that is, they inhibited bacterial growth of either friendly or pathogenic bacteria — and the lead candidate, prevotellin-2, demonstrated anti-infective capabilities on par with polymyxin B, an FDA-approved antibiotic used today to treat multidrug-resistant infections, suggesting that the human gut microbiome may contain antibiotics that will someday find clinical application. “Identifying prevotellin-2, which has activities on par with one of our antibiotics of last resort, polymyxin B, was very surprising to me,” says Bhatt. “This suggests that mining the human microbiome for new and exciting classes of antimicrobial peptides is a promising path forward for researchers and doctors, and most especially for patients.” Reference: “Mining human microbiomes reveals an untapped source of peptide antibiotics” by Marcelo D.T. Torres, Erin F. Brooks, Angela Cesaro, Hila Sberro, Matthew O. Gill, Cosmos Nicolaou, Ami S. Bhatt and Cesar de la Fuente-Nunez, 19 August 2024, Cell. DOI: 10.1016/j.cell.2024.07.027 Professor de la Fuente holds a Presidential Professorship at the University of Pennsylvania and is supported by funding from Procter & Gamble, United Therapeutics, a Brain & Behavior Research Foundation Young Investigator Grant, the Nemirovsky Prize, Penn Health-Tech Accelerator Award, the Defense Threat Reduction Agency (HDTRA11810041 and HDTRA1-23-1-0001), and the Dean’s Innovation Fund from the Perelman School of Medicine at the University of Pennsylvania. Professor Bhatt was supported by a Paul Allen Distinguished Investigator Award and the NIH (R01AI148623 and R01AI143757). Research reported in this publication was supported by the Langer Prize (American Institute of Chemical Engineers Foundation), the National Institutes of Health (R35GM138201), and the Defense Threat Reduction Agency (HDTRA1-21-1-0014).

Researchers have identified a new method the immune system uses to eliminate cells that don’t have CD47 molecules marking them as “self”, with dendritic cells directly killing these CD47-lacking T cells. This discovery offers a fresh perspective for potential cancer treatments. Scientists have found that dendritic cells eliminate CD47-deficient T cells, opening potential new avenues for cancer therapy by modifying CD47 expression. Researchers from Kobe University have identified an entirely new and unexpected mechanism through which the immune system eliminates cells lacking molecules that identify them as part of the self in mice. This discovery, published in the journal Proceedings of the National Academy of Sciences, may have potential implications for cancer therapy. The immune system comprises many types of cells that work together to fight off diseases. Two important types are dendritic cells and T cells. Dendritic cells are located in strategic positions throughout the body including the gut and skin, as well as in the lymph nodes, sample their environment and present small components derived from these samples on their surface. T cells check these samples and if they recognize them as foreign (or “non-self”), they will initiate an immune response, otherwise, they will move on. The ability to distinguish self from non-self is therefore a key characteristic of the immune system and T cells undergo very selective training, by dendritic cells, to make sure they can make that distinction. The cells in our body display several molecules on their surface that identify them as “self” to immune cells. One of these self-identifying molecules is CD47. It was known that if T cells lack CD47, they would be efficiently eliminated by other immune cells. However, various experiments with mice lacking CD47 failed to produce an indication of the molecular mechanism of which cells were responsible for the elimination. It was known that T cells are killed when they lack a surface molecule called CD47. Now, a research group at Kobe University has identified the culprit and discovered an unexpected capability of the immune system that has the potential for cancer treatment. Credit: Professor Nitta Ryo (Graduate School of Medicine, Division of Structural Medicine and Anatomy, Kobe University) Now, the research group of Associate Professor Saito Yasuyuki, Postdoctoral fellow Komori Satomi, and Specially Appointed Professor Matozaki Takashi at Kobe University, that has been working on the molecular interaction between dendritic cells and T cells and in particular on the role of CD47 in that process, tried a novel approach. Saito explains: “We generated genetically modified mice in which only T cells lack CD47. This is quite different from the conventional approach with mice that systematically lack CD47 on all cells.” This new approach enabled them to isolate the role of CD47 on T cells from other factors that might influence the interaction. A Novel Role for Dendritic Cells in Inducing Cell Death Their results, published in the journal PNAS, clearly identified dendritic cells as those killing T cells lacking CD47. Not only does this for the first time shed light on the mechanism behind the disappearance of CD47-deficient T cells, it also reveals a completely unexpected capability of dendritic cells. “This result is totally novel because it was believed that CD47-deficient cells are engulfed by a type of immune cells called ‘macrophages’ and that dendritic cells never induce cell death in other immune cells,” says Saito. The team thus found an entirely new way in which the body identifies missing-self cells, that is, cells lacking CD47 being killed directly by dendritic cells. This finding also suggests a new line of research. Now that this new ability of dendritic cells has been discovered, is it used on other kinds of cells, too, and can it be used therapeutically? Saito says: “Our results raise the question: do dendritic cells induce cell death in other cells that lack CD47? This question is so important because this novel mechanism can be applied to the induction of cell death by modification of CD47 on target cells, such as cancer cells.” The group has already initiated further research projects to clarify these questions and also to better understand the mechanism behind this newly-discovered capability of dendritic cells. They have also started work to verify the potential of treating cancer based on this novel finding. Reference: “CD47 promotes peripheral T cell survival by preventing dendritic cell–mediated T cell necroptosis” by Satomi Komori, Yasuyuki Saito, Taichi Nishimura, Datu Respatika, Hiromi Endoh, Hiroki Yoshida, Risa Sugihara, Rie Iida-Norita, Tania Afroj, Tomoko Takai, Okechi S. Oduori, Eriko Nitta, Takenori Kotani, Yoji Murata, Yoriaki Kaneko, Ryo Nitta, Hiroshi Ohnishi and Takashi Matozaki, 7 August 2023, Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.2304943120 The study was funded by the Japan Agency for Medical Research and Development (AMED) Project for Accelerating Next-Generation Cancer Treatment (P-PROMOTE), the Project for Creation of Next-Generation Cancer Treatment (P-CREATE), and the JST Co-creation Opportunity Formation Support Program (COI-NEXT).

DVDV1551RTWW78V